Quest Diagnostics (NYSE:DGX) has issued its FY 2026 earnings guidance, projecting an EPS of 9.45-9.65, which is below the consensus estimate of 10.41. Despite this, the company reported strong Q4 results, beating analyst estimates for both EPS and revenue. Insider selling was noted, but analysts maintain an average “Moderate Buy” rating with a target price of $198.50.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Quest Diagnostics (NYSE:DGX) Issues FY 2026 Earnings Guidance
Quest Diagnostics (NYSE:DGX) has issued its FY 2026 earnings guidance, projecting an EPS of 9.45-9.65, which is below the consensus estimate of 10.41. Despite this, the company reported strong Q4 results, beating analyst estimates for both EPS and revenue. Insider selling was noted, but analysts maintain an average “Moderate Buy” rating with a target price of $198.50.